BioTrends provides an email subscription service for its news releases
Please click the link below to subscribe:
Subscribe Here
RHEUMATOLOGISTS HAVE PLENTY OF CHOICE AMONG BIOLOGIC AGENTS FOR RA – WHERE WILL ACTEMRA FIND ITS NICHE?
NEW STUDY BY BIOTRENDS HIGHLIGHTS CHANGES IN THE MANAGEMENT OF GOUT AND HYPERURICEMIA AMONG RHEUMATOLOGISTS AND PRIMARY CARE PHYSICIANS
STELARA IMPRESSES WITH EFFICACY DATA AND DOSING CONVENIENCE, BUT SAFETY CONCERNS LIKELY TO IMPACT NEAR TERM UPTAKE
Use of AMAG’s Feraheme is on the Rise with 23% of Nephrologists Reporting Use of the Product
Page 1 of 12
